Kura Oncology, Inc. (KURA): Capital Expenditures
$6.64M
Year ended 2025-12-31
$5.67M
Trailing 12 months to 2026-06-30
+119.7%
3-year compound annual growth
+25.0%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.64M | n/m | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $472.0K | +181.0% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $168.0K | -73.2% | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $626.0K | -45.4% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $1.15M | -47.2% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $2.17M | n/a | 2023-02-23, From 2020-01-01 |
| No annual figure between 2015-12-31 and 2020-12-31. | |||
| 2015-12-31 | $64.0K | n/a | 2017-03-14, From 2015-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $6.64M | n/m |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $542.0K | -46.4% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $12.90M | -28.1% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $495.0K | -3.1% |
| Fortress Biotech, Inc. (FBIO) | 2024-12-31 | $0 | -100.0% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $66.0K | +135.7% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $2.35M | +90.3% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $1.05M | +39.0% |
| Journey Medical Corp (DERM) | 2024-12-31 | $15.00M | +200.0% |
Compare KURA, RMTI, ENTA, VRDN side by side · Screen every company in Pharmaceutical Preparations ↗